Ossiam Has $2.27 Million Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Ossiam increased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 102.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,583 shares of the medical equipment provider’s stock after acquiring an additional 8,882 shares during the quarter. Ossiam’s holdings in Zimmer Biomet were worth $2,272,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Cutler Group LLC CA acquired a new position in shares of Zimmer Biomet in the 1st quarter valued at $25,000. Clear Street Markets LLC acquired a new position in Zimmer Biomet in the fourth quarter worth $27,000. Orion Capital Management LLC boosted its stake in Zimmer Biomet by 234.7% in the first quarter. Orion Capital Management LLC now owns 251 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 176 shares in the last quarter. Dark Forest Capital Management LP acquired a new position in Zimmer Biomet in the first quarter worth $35,000. Finally, Horizon Bancorp Inc. IN bought a new position in shares of Zimmer Biomet in the fourth quarter valued at about $38,000. 87.48% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, Director Arthur J. Higgins purchased 1,000 shares of the stock in a transaction on Wednesday, August 23rd. The shares were purchased at an average cost of $115.61 per share, for a total transaction of $115,610.00. Following the purchase, the director now owns 3,400 shares of the company’s stock, valued at $393,074. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, Director Michael W. Michelson purchased 1,300 shares of the company’s stock in a transaction on Friday, August 25th. The shares were purchased at an average cost of $115.50 per share, with a total value of $150,150.00. Following the completion of the transaction, the director now owns 3,385 shares of the company’s stock, valued at approximately $390,967.50. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Arthur J. Higgins acquired 1,000 shares of the stock in a transaction dated Wednesday, August 23rd. The shares were purchased at an average price of $115.61 per share, for a total transaction of $115,610.00. Following the completion of the purchase, the director now directly owns 3,400 shares in the company, valued at $393,074. The disclosure for this purchase can be found here. Insiders acquired 5,300 shares of company stock valued at $619,090 in the last ninety days. 0.95% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms recently issued reports on ZBH. Barclays lifted their price target on Zimmer Biomet from $116.00 to $120.00 and gave the company an “underweight” rating in a report on Wednesday, August 2nd. BTIG Research raised Zimmer Biomet from a “neutral” rating to a “buy” rating and set a $139.00 price objective on the stock in a report on Monday, August 28th. StockNews.com initiated coverage on Zimmer Biomet in a report on Thursday, August 17th. They set a “buy” rating on the stock. Stifel Nicolaus boosted their target price on Zimmer Biomet from $160.00 to $165.00 in a research report on Thursday, May 18th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $160.00 price objective on shares of Zimmer Biomet in a research report on Wednesday, August 2nd. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $145.16.

Zimmer Biomet Stock Up 0.1 %

Shares of ZBH stock opened at $120.65 on Monday. The firm has a fifty day moving average of $129.83 and a 200-day moving average of $131.61. The company has a quick ratio of 0.95, a current ratio of 1.96 and a debt-to-equity ratio of 0.42. Zimmer Biomet Holdings, Inc. has a 12-month low of $102.60 and a 12-month high of $149.25. The company has a market capitalization of $25.21 billion, a price-to-earnings ratio of 50.06, a P/E/G ratio of 2.37 and a beta of 1.04.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Tuesday, August 1st. The medical equipment provider reported $1.82 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.82. The firm had revenue of $1.87 billion during the quarter, compared to analyst estimates of $1.83 billion. Zimmer Biomet had a net margin of 7.03% and a return on equity of 12.36%. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period in the prior year, the business earned $1.82 EPS. As a group, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 7.51 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, October 31st. Stockholders of record on Friday, September 29th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $0.96 annualized dividend and a dividend yield of 0.80%. Zimmer Biomet’s dividend payout ratio is currently 39.83%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.